Danon disease (DD) is a rare X-linked disorder caused by loss-of-function mutations in the LAMP2 gene, which encodes lysosome-associated membrane protein. It is characterized by the triad of hypertrophic cardiomyopathy, myopathy, and intellectual disability.
| INTRODUCTION
Danon disease (DD) is an X-linked metabolic disorder, also referred to as lysosomal glycogen storage disease (type IIb or Pompe with normal acid maltase; Danon et al., 1981) . It was originally described by Danon et al. (1981) in two unrelated cases of 16 years old boys with triad of symptoms: cardiomyopathy, skeletal myopathy, and intellectual disability. Most of the mutations associated with the disorder lead to a null allele resulting in absence or severe depletion of LAMP2 protein expression (Nishino et al., 2000) . Males usually develop the condition earlier than females and show a severe, rapidly progressive disease trajectory. Consequently, affected men live on average to the age of 19 years, while affected women live to an average age of 34.6 (Boucek, Jirikowic, & Taylor, 2011) .
Whereas the clinical phenotypes of the disorder are relatively well-known (Maron et al., 2009; Nishino et al., 2000) , the cognitive deficits and psychiatric comorbidities manifesting in DD remain an understudied topic that merits further investigation. While the current literature suggests that most men and a fraction of affected women have intellectual disability (Sugie et al., 2002 (Sugie et al., , 2016 , to the best of our knowledge, cognitive abilities were not rigorously assessed in previous studies (Boucek et al., 2011; Danon et al., 1981) . Same goes with reports on psychiatric comorbidities in DD which are almost entirely missing from DD medical literature (Hatz, Sharma, Germer, Rolfsmeyer, & Bowen, 2010; Tanidir, Tanidir, & Tuzcu, 2015) . In one study, formal IQ tests were performed in five male patients and their IQ was found to be in a range of 60-91 (Sugie et al., 2002) .
Of note, the term "mental retardation" was originally used to describe the cognitive complaints in affected individuals, but since the publication of DSM-5 (American Psychiatric Association, 2013) the term was replaced to "intellectual disability" which we will use hereafter in the manuscript.
The purpose of the current study was to thoroughly characterize the cognitive and psychiatric profiles of individuals diagnosed with DD.
| MATERIALS AND METHODS

| Participants
Thirteen participants (five males and eight females) with genetically confirmed LAMP2 mutations were enrolled to the study. The patients originated from five medical centers at three different countries: Israel (n = 8), Spain (n = 4), and Italy (n = 1) (see Table 1 for participants' sociodemographic characteristics). The Israeli cohort included all known living DD individuals currently residing in Israel, all being Ashkenazi Jews who carry the same founder mutation. The study was approved by the Institutional Review Boards (IRB) of the participating sites. An informed consent was obtained from participants and from parents of minors.
| Cognitive assessment
Full-scale IQ scores (FSIQ) of twelve participants were calculated using the age-appropriate version of the Wechsler Intelligence test (Wechsler, 1997) . In addition, seven Israeli participants underwent comprehensive neurocognitive assessment using the Penn Computerized Neurocognitive Battery (CNB) (Gur et al., 2010) . The CNB is a single computerized battery which rules out potential limitations of combining tests from multiple batteries, and it is suggested to correlate with IQ (Swagerman et al., 2016) . The CNB is widely employed in individuals with genetic syndromes (Weinberger et al., 2016) . slower response time is reflected in lower scores and vice versa. Scores lower than −4 were set to a floor value of −4 to reduce the influence of outliers. Finally, efficiency scores were calculated by taking the arithmetic mean of the accuracy and speed scores. Global Neurocognitive Performance (GNP) score was calculated as the mean of all efficiency scores of the different modules of the battery.
| Psychiatric assessment
All participants underwent psychiatric assessment. The Schedule for Affective Disorders and Schizophrenia for School-Aged Children, Present and Lifetime (K-SADS-PL) was used to assess psychopathology in children and adolescents up to age 18 (Kaufman et al., 1997) , and the Structured Clinical Interview (SCID) was used in case of adults (First, Spitzer, Gibbon, & Williams, 1997) .
| Medical and genetic characteristics
The present cohort included 13 patients, 5 males and 8 females. At the time of the study the age of the participants ranged from 17 to 57 years (mean age = 36.23 years, SD = 16.06). Participants had cardiological manifestations including Wolff-Parkinson-White (WPW), hypertrophic or dilated cardiomyopathy and congestive heart failure to various extents (Table 2) . Of note, patients #1 and #3 were referred to the metabolic clinic for evaluation of hypertransaminasemia for evaluation of failure to thrive at age 6 months and prior to starting Ritalin (methylphenidate) due to ADHD at age 6 years, respectively. Their molecular diagnosis was established at age 10 and 8 years, respectively, while having no cardiological symptoms. No ophthalmological abnormalities were reported in this cohort. Three females (#2, #4, and #6) did not manifest any of the classical features of Danon disease and were therefore designated as carriers. Patients #1-8, originating from the same Israeli kindred had the same splice site mutation. The other five participants had stop codon mutations.
| Cognitive characteristics
The and 105 points). Two participants had borderline intelligence (see patients #3 and #6 in Table 3 ), and only one patient had a score within the range of intellectual disability (patient #12).
On the CNB, the mean GNP score was −0.94 (an equivalent to a FSIQ score of 86) with SD of 0.95, with more pronounced deficit in the executive function domain (−1.72 ± 1.27), compared to all other domains (which ranged between −0.96 and −0.34; Figure 1 ). 
| Psychiatric comorbidities
At the time of psychiatric evaluation, nine participants (69.2%) met criteria for at least one psychiatric disorder (Table 2) . We observed high rates of mood disorders (found in 6 out of 13 participants, 46.15%), including: major depression disorder (MDD; n = 3), and dysthymia (n = 3). Similarly, 6 out of 13 individuals met criteria for an anxiety disorder (46.15%), including: general anxiety disorder (GAD; n = 3), social anxiety disorder (SAD; n = 2), panic disorder (n = 1), and specific phobia (n = 1). Two patients were diagnosed also with attention deficit/hyperactivity disorder (ADHD), alongside a diagnosis of either oppositional defiant disorder (ODD; patient #3) or dysthymia (patient #6). One patient who was diagnosed with SAD and specific phobia (#1) also met criteria for the diagnosis of obsessive-compulsive disorder (OCD).
Finally, 2 female carriers ("asymptomatic carriers") were found to have psychiatric comorbidities, including dysthymia, ADHD, and GAD.
| Detailed clinical reports
Patients #1 and #5 originated from the same Israeli kindred (detailed article in preparation). About 50 years ago the first grandparent of this kindred was described (Kariv, Kreisler, Sherf, Feldman, & Rosenthal, 1971 and had panic attacks since she can remember herself. She was diagnosed with panic disorder and agoraphobia when she was 10 years old. In the current psychiatric interview, she met criteria for dysthymia and panic disorder. At the time of assessment, she was receiving psychotherapy combined with trazodone and duloxetine.
| DISCUSSION
Our study is the first to systematically assess the cognitive and psychiatric characteristics of males and females diagnosed with DD.
We found that most patients have an IQ score within the normal range and only one patient had intellectual disability. Cognitive testing further revealed a relative weakness of DD patients in the domain of executive function. These findings partially contrast earlier reports, including the original description of the disease by Dr. Danon, which referred to intellectual disability as one of the disease's triad of symptoms (Boucek et al., 2011; Danon et al., 1981) . However, only a few studies assessed IQ and cognitive abilities using formal psychometric tests, and the ones to do so were either confined to small sample size or holds standardized data only on part of the sample (Sugie et al., 2002 (Sugie et al., , 2016 ).
An earlier investigation reported that mental retardation was observed in 14 affected males (70% of that sample) and one affected female (6% of the sample). However, IQ was formally assessed only in 5 out of 20 males (Sugie et al., 2002) . Another study that reported the findings of 82 individuals with DD from 36 families reported that mild to moderate learning or cognitive disabilities existed in all males and approximately half of affected females (Boucek et al., 2011) . However, this study was based on registry data, not on direct clinical/cognitive assessment. A recent case report of a 12 years old girl with DD (Sugie et al., 2016) indicated that she had a learning disability and an intellectual disability, and an IQ score of 78 points, within the borderline range of intelligence, with perceptual reasoning being higher than verbal comprehension.
As our analysis suggest that when the cognitive abilities of DD patients are assessed using standardized cognitive measurements, most of them are not shown to have intellectual disability/mental retardation but rather milder cognitive (eg, executive functioning) deficits.
The second novel finding concerns the high rates of psychiatric comorbidities, especially anxiety disorders and mood disorders, found in our sample of 13 individuals. More than two-thirds (69.2%) of the participants met criteria for at least one psychiatric disorder, and approximately half of participants (53.8%) were diagnosed with two or more psychiatric comorbidities. In addition, comorbidities were as common in hemizygous males as in heterozygous females and, remarkably, were present even in female "carriers" considered so far to be asymptomatic.
Although patients with cardiomyopathy are known to have higher incidence of mood and anxiety disorders (Dickens, Cherrington, & McGowan, 2012) , reports regarding psychiatric illness in DD are scarce. In fact, to date, there are only two single case-studies describing clinical/psychiatric symptoms in individuals with DD. One study described the case of a 19 years old male with ADHD who developed psychosis and suicidal ideations few years after undergoing a heart transplant (Hatz et al., 2010) . The second case study described a 16 years old male with mood and anxiety symptoms (Tanidir et al., 2015) . Our findings indicate that clinicians and caregivers dealing with DD patients should be aware of their proneness towards depressive and anxiety disorders.
Moreover, these psychiatric comorbidities may affect compliance with the medical treatment and activity recommendations given to DD patients due to their cardiac condition. Since effective regimens such as CBT and selective serotonin reuptake inhibitors (SSRIs) are readily available (Hofmann, Asnaani, Vonk, Sawyer, & Fang, 2012; Papakostas et al., 2008) , timely psychiatric evaluation is warranted in all newly diagnosed subjects with LAMP2 mutations, regardless of whether they show the typical DD medical (cardiac) symptoms or not.
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